Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1596109

Cover Image

PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1596109

Human Growth Hormone Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)

PUBLISHED:
PAGES: 230 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4900
Printable PDF (Group User License)
USD 6400
Printable PDF (Enterprise License)
USD 8400

Add to Cart

Market Overview

The global human growth hormone (HGH) market is projected to reach $14,497.0 million by 2030, advancing at a compound annual growth rate (CAGR) of 15.2% from its estimated value of $6,199.8 million in 2024. This significant growth is primarily driven by the increasing prevalence of hormonal disorders and the robust product pipelines of pharmaceutical and biopharmaceutical companies worldwide.

The pituitary gland-produced peptide hormone plays a crucial role in stimulating growth during childhood and adolescence, influencing skeletal development and various metabolic processes. Advancements in recombinant DNA technology have facilitated the development of HGH therapies, enhancing their efficacy and safety profiles. Additionally, the approval and introduction of novel therapies, such as the FDA-approved somatrogon by Pfizer and OPKO Health Inc. in January 2021, are expected to further propel market expansion.

Key Insights

The HGH market is categorized into short-acting and long-acting products. The long-acting segment is anticipated to witness substantial growth due to the convenience of reduced dosing frequency, improving patient compliance. HGH therapies are utilized for various conditions, including growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, and individuals small for gestational age. The increasing incidence of these disorders is contributing to the heightened demand for HGH treatments. Hospital pharmacies represent the largest distribution channel category, reflecting the critical role of healthcare institutions in administering HGH therapies. However, retail and online pharmacies are gaining traction, offering patients greater accessibility and convenience.

North America holds the largest share of the HGH market, attributed to advanced healthcare infrastructure and high awareness levels. Conversely, the Asia-Pacific region is expected to experience the fastest growth, driven by increasing healthcare investments and rising awareness of hormonal disorders. Ongoing research and development efforts are focused on creating HGH formulations with minimal side effects and enhanced therapeutic efficacy. Innovations in drug delivery systems and recombinant DNA technology are pivotal in shaping the future landscape of HGH therapies.

The HGH market is consolidated, with key players actively engaging in strategic initiatives such as product launches, collaborations, and mergers to strengthen their market positions. The introduction of novel therapies and expansion into emerging markets present significant opportunities for industry participants.

Product Code: 10435

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by product type
    • 1.4.2. Market size breakdown, by indication
    • 1.4.3. Market size breakdown, by distribution channel
    • 1.4.4. Market size breakdown, by region
    • 1.4.5. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Product Type (2019-2030)
  • 6.3. Market Revenue, by Indication (2019-2030)
  • 6.4. Market Revenue, by Distribution Channel (2019-2030)
  • 6.5. Market Revenue, by Region (2019-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Product Type (2019-2030)
  • 7.3. Market Revenue, by Indication (2019-2030)
  • 7.4. Market Revenue, by Distribution Channel (2019-2030)
  • 7.5. Market Revenue, by Country (2019-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Product Type (2019-2030)
  • 8.3. Market Revenue, by Indication (2019-2030)
  • 8.4. Market Revenue, by Distribution Channel (2019-2030)
  • 8.5. Market Revenue, by Country (2019-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Product Type (2019-2030)
  • 9.3. Market Revenue, by Indication (2019-2030)
  • 9.4. Market Revenue, by Distribution Channel (2019-2030)
  • 9.5. Market Revenue, by Country (2019-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Product Type (2019-2030)
  • 10.3. Market Revenue, by Indication (2019-2030)
  • 10.4. Market Revenue, by Distribution Channel (2019-2030)
  • 10.5. Market Revenue, by Country (2019-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Product Type (2019-2030)
  • 11.3. Market Revenue, by Indication (2019-2030)
  • 11.4. Market Revenue, by Distribution Channel (2019-2030)
  • 11.5. Market Revenue, by Country (2019-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Product Type (2019-2030)
  • 12.3. Market Revenue, by Indication (2019-2030)
  • 12.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Product Type (2019-2030)
  • 13.3. Market Revenue, by Indication (2019-2030)
  • 13.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Product Type (2019-2030)
  • 14.3. Market Revenue, by Indication (2019-2030)
  • 14.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Product Type (2019-2030)
  • 15.3. Market Revenue, by Indication (2019-2030)
  • 15.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Product Type (2019-2030)
  • 16.3. Market Revenue, by Indication (2019-2030)
  • 16.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Product Type (2019-2030)
  • 17.3. Market Revenue, by Indication (2019-2030)
  • 17.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Product Type (2019-2030)
  • 18.3. Market Revenue, by Indication (2019-2030)
  • 18.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Product Type (2019-2030)
  • 19.3. Market Revenue, by Indication (2019-2030)
  • 19.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Product Type (2019-2030)
  • 20.3. Market Revenue, by Indication (2019-2030)
  • 20.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Product Type (2019-2030)
  • 21.3. Market Revenue, by Indication (2019-2030)
  • 21.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Product Type (2019-2030)
  • 22.3. Market Revenue, by Indication (2019-2030)
  • 22.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Product Type (2019-2030)
  • 23.3. Market Revenue, by Indication (2019-2030)
  • 23.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Product Type (2019-2030)
  • 24.3. Market Revenue, by Indication (2019-2030)
  • 24.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Product Type (2019-2030)
  • 25.3. Market Revenue, by Indication (2019-2030)
  • 25.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Product Type (2019-2030)
  • 26.3. Market Revenue, by Indication (2019-2030)
  • 26.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Product Type (2019-2030)
  • 27.3. Market Revenue, by Indication (2019-2030)
  • 27.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Product Type (2019-2030)
  • 28.3. Market Revenue, by Indication (2019-2030)
  • 28.4. Market Revenue, by Distribution Channel (2019-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. Pfizer Inc.
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. F. Hoffmann-La Roche AG
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Novo Nordisk A/S
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. Merck KGaA
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. Eli Lilly and Company
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. Novartis AG
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. Teva Pharmaceutical Industries Ltd.
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. AnkeBio Co. Ltd.
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. Ipsen S.A.
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!